GNI Group Ltd (2160):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GNI Group Ltd (2160) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8004
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GNI Group Ltd (GNI) is a healthcare service provider that researches, develops, manufactures and markets pharmaceutical drugs. The company’s business operations consist of drug discovery activities such as drug discovery research, drug discovery infrastructure, fundamental drug discovery, and others. It provides products such as Etuary, F351, F573, and Tamibarotene drugs. GNI’s Etuary offers anti-inflammatory, anti-oxidation, anti-fibrotic effects, and others. The company conducts research in the areas of chronic kidney disease, liver disease and interstitial lung disease; and treatment studies include connective tissue disease associated interstitial lung disease, radiation pneumonitis and diabetic nephropathy, among others. Its drugs are used in the treatment of pulmonary fibrosis, liver fibrosis, kidney fibrosis, and others. GNI is headquartered in Tokyo, Japan.

GNI Group Ltd (2160) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GNI Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GNI Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GNI Group Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cullgen Raises up to USD15 Million in Seed Financing 11
Partnerships 12
EPS Forms Joint Venture With GNI Group 12
Licensing Agreements 13
GNI Enters Into Licensing Agreement With AFT Pharma For Etuary 13
Acquisition 14
GNI Group to Acquire 53% Stake in GNI-EPS for USD4.2 Million 14
GNI Group Ltd – Key Competitors 15
GNI Group Ltd – Key Employees 16
GNI Group Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Strategy And Business Planning 18
Aug 29, 2017: GNI Group announces that Beijing Continent’s formal ribbon-cutting ceremony for new factory 18
Other Significant Developments 19
Jul 04, 2018: GNI Group: The progress of construction of Beijing Continent’s new plant in Hebei province 19
Mar 06, 2018: Henan Province include IPF into its Important, Special, and Major Disease Outpatient Insurance 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
GNI Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GNI Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GNI Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
GNI Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cullgen Raises up to USD15 Million in Seed Financing 11
EPS Forms Joint Venture With GNI Group 12
GNI Enters Into Licensing Agreement With AFT Pharma For Etuary 13
GNI Group to Acquire 53% Stake in GNI-EPS for USD4.2 Million 14
GNI Group Ltd, Key Competitors 15
GNI Group Ltd, Key Employees 16
GNI Group Ltd, Subsidiaries 17
GNI Group Ltd, Joint Venture 17

List of Figures
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GNI Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GNI Group Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[GNI Group Ltd (2160):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MorphoSys AG (MOR):企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid a …
  • HAI Argochem (HAI):企業の財務・戦略的SWOT分析
    HAI Argochem (HAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Decmil Group Ltd (DCG):企業の財務・戦略的SWOT分析
    Summary Decmil Group Ltd (Decmil), is a provider of construction, engineering and accommodation and project management services. The company provides services such as design, accommodation services, civil engineering, construction, and maintenance services, among others. Decmil provides government i …
  • Axikin Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Axikin Pharmaceuticals Inc (Axikin) is a biopharmaceutical company that develops small molecule therapeutics for respiratory disorders. The company offers pre-clinical and research programs with small molecule therapeutics for applications in asthma, chronic obstructive pulmonary disease, in …
  • Saigon Thuong Tin Commercial Joint Stock Bank:企業の戦略・SWOT・財務分析
    Saigon Thuong Tin Commercial Joint Stock Bank - Strategy, SWOT and Corporate Finance Report Summary Saigon Thuong Tin Commercial Joint Stock Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Champion Aerospace LLC:企業の戦略・SWOT・財務情報
    Champion Aerospace LLC - Strategy, SWOT and Corporate Finance Report Summary Champion Aerospace LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Gold Fields Ltd:戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Rex Energy Corp (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds pro …
  • Ambu AS (AMBU B):医療機器:M&Aディール及び事業提携情報
    Summary Ambu A/S (Ambu) is a medical device company that manufactures and markets life supporting devices. It focuses on single-use devices for anesthesia, patient monitoring and diagnostics, and emergency care. It serves hospitals, clinics, sleep laboratories and rescue services. The major products …
  • Cargolux Airlines International S.A.:企業の戦略的SWOT分析
    Cargolux Airlines International S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Lab21 Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Lab21 Ltd (Lab21), a subsidiary of Novacyt SA, is a clinical laboratory that offers clinical diagnostic testing services. The company develops molecular diagnostics for oncology and virology. Its oncology includes KRAS, EGFR, BRAF, ALK, RAS-RAF, BRCA, prostate cancer, among others. Lab21’s v …
  • BioMark Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • Carna Biosciences Inc (4572):製薬・医療:M&Aディール及び事業提携情報
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Saudi Industrial Services Co (2190):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Services Co (SISCO) is an investment holding company that develops and invests in the water, wastewater, energy, IT, sewage, and communications business. The company undertakes large scale capital investment in desalination plants, industrial estate development, free zone po …
  • Mentor Graphics Corporation:企業のM&A・事業提携・投資動向
    Mentor Graphics Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mentor Graphics Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • TTEC Holdings Inc (TTEC):企業の財務・戦略的SWOT分析
    TTEC Holdings Inc (TTEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Meridian Bancorp, Inc. (EBSB):企業の財務・戦略的SWOT分析
    Meridian Bancorp, Inc. (EBSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆